| Hazard Information | Back Directory | [Uses]
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2]. | [in vivo]
Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats[1].
| Animal Model: | Sprague-Dawley rats [2] | | Dosage: | 1, 10, and 100 mg/kg | | Administration: | Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study) | | Result: | Observed the bone anabolic effects.
Showed significant bleeding and morbidity at 100 mg/kg.
Decreases in the numbers of platelets.
Increased number of bone marrow megakaryocytes at 100 mg/kg.
|
| [References]
[1] Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24. DOI:10.1002/jbmr.2351
[2] Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. DOI:10.1093/toxsci/kfr318 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|